ENHERTU approved in the U.S. as the first HER2 directed for low metastatic breast cancer

Based on DESTINY-Breast04 results which showed Daiichi Sankyo and AstraZeneca’s ENHERTU reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy

HERTHENA-Lung02 Phase 3 trial of Patritumab Deruxtecan initiated in patients with EGFR-mutated metastatic non-small cell lung cancer

Patritumab deruxtecan is a specifically designed potential first-in-class HER3 directed antibody drug conjugate (ADC) discovered and being developed by Daiichi Sankyo.

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

Ascentage Pharma and Tanner Pharma Group initiate a global innovative named Patient Program

Tanner will be the supplier of olverembatinib to healthcare providers on a named patient basis in countries where the drug is not commercially available.

DS-7300 Phase 2 Trial Initiated in Patients with Pretreated ExtensiveStage Small Cell Lung Cancer

DS-7300 is a specifically designed potential first-in-class B7-H3 directed antibody drug conjugate

Merck updates on Phase 3 Keynote-412 trial in advanced head and neck squamous cell carcinoma

Strand Life Sciences presents report on ‘Genomic Surveillance of SARS-CoV-2’

Strand Life Sciences has sequenced a total of 12800 samples from July, 2021 to June, 2022, and identified more than a 100 lineages circulating in Bengaluru

W.R. Grace to expand capacity at small-molecule API plant

The expansion at CDMO facility in South Haven, will bring a new 4,000-gallon multi-use reactor train consisting of glass lined and stainless-steel materials of construction

Regeneron completes purchase of Sanofi's stake in Libtayo

Company provides anticipated impact to second quarter 2022 financial results due to recently completed business development transactions